Blocking the TL1A signaling pathway using an anti-TL1A antibody in colitis or asthma animal models has been shown to attenuate pathology and inflammation in these disease models (67), further highlighting TL1A as a promising marker for therapeutic strategies against inflammatory disease. This evidence concerns the gene TNFSF15 and asthma.